Victoria's Secret Q1 Preview: Poison Pill Narrative Should Dominate The Call

  • Victoria's Secret & Co. Q1 results are expected to be unremarkable, with sales and EPS in line with management and analyst guidance. The main VSCO focus is the hostile takeover attempt by BBRC, countered by a poison pill defense to protect existing shareholders from losing control. BBRC's 13% stake and potential to reach 49.99% create uncertainty, with the board aiming to prevent a single investor's dominance.